7-Chloro-4,4-dimethyl-3,4-dihydronaphthalen-1(2H)-one, 95%, 1g

4-Methyl-1H-indazole, 95.0%, 10g

3-Isochromanone, 95.0%, 100g

5-METHOXY-2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENOL, 95%, 100mg

2-Chloro-5-pyridinylhydrazine, 95.0%, 1g

(2S,4R)-1-(tert-Butoxycarbonyl)-4-(4-methylbenzyl)pyrrolidine-2-carboxylic acid, 95.0%, 250mg

Ethyl 3,4-diaminobenzoate, 95.0%, 500g

Plan PLPHi S100x/1,25 objectif corrigé à l'infini pour IOS à contraste de phase

IPA-3, 95%, 10mg

Acenaphthylene, 95.0%, 100g

2,6-Dichloro-5-(trifluoromethyl)nicotinonitrile, 95.0%, 100mg

1-(1H-1,2,4-triazol-3-ylcarbonyl)piperazine hydrochloride, 95.0%, 1g

Fmoc-allo-Thr-OH, 95.0%, 5g